AzTrials
AzTrials

Covid19VETextNCT04805931

VEText Message Framing and Covid-19 Vaccine Uptake Among at Risk Veterans

A study testing Behavioral economics in people with Covid19 and Vaccine Refusal, run by VA Puget Sound Health Care System at 1 site in United States.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This is a prospective, randomized controlled trial that will evaluate the effectiveness of two different targeted outreach interventions aimed at increasing Covid-19 vaccine uptake. Veterans who are eligible for COVID-19 vaccine receipt by priority status (based on institutional guidelines) will be identified. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Covid19, Vaccine Refusal
What is being tested?
Behavioral economics
Could I receive a placebo?
No, everyone receives an active treatment
How many people
4,311 participants
Where
1 siteUnited States
Study dates
15 Mar 2021to 1 Nov 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Veterans must be enrolled into VHA care
  • Veterans must meet age or illness institutional priority guidelines for eligibility for COVID-19 vaccine receipt

Who cannot join

  • None

Trial locations and contacts

1 site in 1 country.

Alaina Mori, BA contact

(206) 247-6782

alaina.mori@va.gov

Stefanie Deeds, MD contact

206-314-0757

Stefanie.Deeds@va.gov

United States1 site, 1 recruiting
  • VA Puget Sound Health Care System

    Seattle, Washington, 98108

    Linnaea Schuttner, MD, 206-277-6126, linnaea.schuttner@va.gov

    Alaina Mori, BA, 206-247-6782, alaina.mori@va.gov

    Recruiting

Other trials in United States

About this study

Official title: COVID-19 Vaccine Rollout: VEText Message Framing and Covid-19 Vaccine Uptake Among at Risk Veterans

This is a prospective, randomized controlled trial that will evaluate the effectiveness of two different targeted outreach interventions aimed at increasing Covid-19 vaccine uptake. Veterans who are eligible for COVID-19 vaccine receipt by priority status (based on institutional guidelines) will be identified. Veterans must be enrolled into Veterans Health Administration (VHA) care and meet age or illness institutional priority guidelines to be eligible. Veterans eligible for enrollment into the trial will be randomized in a 1:1:1 allocation at an individual level, using permuted block randomization (with random block sizes of 3 and 6) to the following interventions:

  1. Control arm - receives a text message with standard messaging
  2. Arm 2 - receives a text message with a message framed for scarcity
  3. Arm 3 - receives a text message with a message framed for improving the social good
Read the detailed description

OBJECTIVE:

To compare the effectiveness of different text message reminders sent through an interactive mobile system (VEText) at increasing Covid-19 vaccine uptake among at risk Veterans.

OVERVIEW:

This is a prospective, randomized controlled trial that will evaluate the effectiveness of two different targeted outreach interventions at increasing Covid-19 vaccine uptake. Veterans who are eligible for Covid-19 vaccine receipt by priority status (based on institutional guidelines) will be identified. Veterans must be enrolled into VHA care and meet age or illness institutional priority guidelines to be eligible. Veterans eligible for enrollment into the trial will be randomized in a 1:1:1 allocation at an individual level, using permuted block randomization (with random block sizes of 3 and 6) to the following interventions:

  1. Control arm - receives a text message with standard messaging
  2. Arm 2 - receives a text message with a behavioral scarcity message
  3. Arm 3 - receives a text message with a behavioral social good message

Randomization will be stratified by VA center (VA Puget Sound or American Lake).

Due to operational constraints, only one type of text message can be sent per day/batch. In order to account for any potential differences with the day of the week the text message is received, the three arm messages will be randomized by day of the week each week. For example, week 1 will have the control group message sent on Monday, the arm 2 message sent on Tuesday, and the arm 3 message sent on Wednesday. Week 2 will have the arm 2 message sent on Monday, the control group message sent on Tuesday, and the arm 3 message sent on Wednesday. Text messages will be sent based on the randomized order generated and will continue on those days of the week that the center has vaccine available.

Our primary outcome of interest is the vaccine scheduling and/or completion rate within 7 days of receipt of the text message. Enrollment in the trial will occur between March 15, 2021 and May 1, 2021.

Primary aims:

Aim 1a: Investigate differences in vaccine scheduling/completion rates among different outreach strategies. Will test the hypothesis (HA1) that the proportion of Veterans either scheduling a vaccine appointment for a first dose or receiving a first vaccine dose varies between targeted behavioral messaging and standard messaging (arms 2 + 3 vs. control) at 7 days post randomization.

Aim 1b: Investigate differences in vaccine scheduling/completion rates among different outreach strategies. Will test the hypothesis (HA1) that the proportion of Veterans either scheduling a vaccine appointment for a first dose or receiving a first vaccine dose varies between different types of behavioral messaging (arm 2 vs. arm 3) at 7 days post randomization.

Secondary aims:

None

Sub-analyses:

None

STUDY POPULATION:

All Veterans who are eligible for a first dose of Covid-19 vaccine by priority status (based on institutional guidelines).

STUDY TIME PERIOD The enrollment period for the study is March 15, 2021 and May 1, 2021. Data collection and analysis will continue through at least 6 months post enrollment for the last Veteran evaluated.

DATA SOURCES:

Table: CDWWork.SVeteran.SMVIPerson Time period: Screening/enrollment Description: Contact information for kit/letter mailing and subsequent reminder calls Variable of interest: Name, address, zip code, phone number, SSN.

Table: CDWWork.SVeteran.SMVIPerson Time period: Screening/enrollment Description: Demographics Analytic variable(s) of interest: DOB, age, gender, marital status, DOD (if applicable), service connectedness, copay.

Table: Communicator report (not CDW table) Time period: Post randomization Description: Provides automated call information Analytic variable(s) of interest: Call date/time, Patient response, Result from non-response.

Table: CDWWork.Appt.Appointment, CDWWork.Dim.Location Time period: Post randomization Description: Scheduled vaccination appointments Analytic variable(s) of interest: Appointment date/time, location.

Table: CDWWork.Immun.Immunization, CDWWork.Dim.ImmunizationName Time period: Post randomization Description: Detailed vaccination receipt records Analytic variable(s) of interest: Vaccine receipt date/time, location.

STATISTICAL ANALYSES AND DESCRIPTION OF MAIN TABLES Sample size analysis assuming a baseline vaccination proportion of approximately 33% among Veterans aged 65 and older (estimates based on vaccination data pulled 03/10/21) the estimated total sample size required to provide at least 80% power to detect a 5% difference between Arms 2 + 3 and the control arm is 4311 total (1437 per group).

Descriptive patient-level statistics will be presented using the Pearson chi-square test for dichotomous variables and the Student's t test for continuous variables. The primary intention-to-treat analysis will use logistic regression to test the association between randomization group and vaccine scheduling/completion 7 days post randomization, adjusting for VHA center as a stratification variable. Odds ratios and predicted probabilities from this model will be reported.

All descriptive and main analyses will be performed using R version 3.6.1. P-values < 0.05 will be considered statistically significant.

  1. Aim 1a Statistical Analyses Will test the hypothesis (HA1) that the proportion of Veterans scheduling an appointment for the first vaccine dose or receiving a first vaccine dose varies between targeted behavioral messaging and standard messaging (arms 2 + 3 vs. control) at 7 days post randomization.
  2. Aim 1b Statistical Analyses Will test the hypothesis (HA1) that different types of behavioral messaging will have differing effects on vaccine scheduling/vaccine completion at 7 days post randomization (arm 2 vs. arm 3)

STUDY OUTCOMES Primary analyses: % of first-dose vaccine appointments scheduled/vaccines completed at 7 days post randomization

STUDY COVARIATES

Primary analyses:

Covariate of interest: intervention group indicator

Being tested
Behavioral economics
Medical subject headings
COVID-19, Vaccination Refusal

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Behavioral economicsBehavioural

    Tailored behavioral economic text messaging vs. standard text messaging

Study groups in NCT04805931
Study groupRoleWhat they receive
ControlNo interventionWill receive a text message with standard messaging used to alert veterans that they are eligible for COVID-19 vaccine and offer scheduling embedded within the text message.
ScarcityExperimentalWill receive a text message with a behavioral scarcity message used to alert veterans that they are eligible for COVID-19 vaccine and offer scheduling embedded within the text message.
Receives: Behavioral: Behavioral economics
Social goodExperimentalWill receive a text message with a behavioral social good message used to alert veterans that they are eligible for COVID-19 vaccine and offer scheduling embedded within the text message.
Receives: Behavioral: Behavioral economics

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Vaccine appointments scheduled/completed

    % of first-dose vaccine appointments scheduled/vaccines completed

    Measured: 7 days post randomization

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Mar 2021
  2. Study start15 Mar 2021
  3. Primary completion1 May 2021
  4. Study completion1 Nov 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Parallel groups
Model description
Prospective, randomized controlled, parallel groups trial
Masking
Single blind
Who is masked
Participant
Enrolment
4,311 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04805931
Sponsor's protocol ID
COVID-19 Vaccine Rollout
Acronym
VEText
Status last verified
Jun 2021
First submitted
11 Mar 2021
Last updated
28 Jun 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Behavioral economics in people with Covid19 and Vaccine Refusal, run by VA Puget Sound Health Care System at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 28 Jun 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Alaina Mori, BA ((206) 247-6782, alaina.mori@va.gov), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Vaccine appointments scheduled/completed (time frame: 7 days post randomization). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jun 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in